ARB Marketers May Be Tense After AHRQ Comparative Effectiveness Report
Executive Summary
A comparative effectiveness review from the Agency for Healthcare Research and Quality comparing ACE inhibitors and ARBs may create challenges for brand manufacturers in formulary negotiations
You may also be interested in...
Baucus Flags Comparative Effectiveness As Priority For Senate Medicare Bill
Comparative effectiveness research continues to have traction in Congress. The issue has been flagged as a priority item for inclusion in the Senate Finance Committee forthcoming package of Medicare and other health care provisions, according to a top health aide to committee Chairman Max Baucus, D-Mont
Savings From Expanded Comparative Effectiveness Could Be Decade Away – CBO
Although medical product comparative effectiveness research is often seen as a way to better target health care spending, an expanded research effort may not yield direct savings for at least 10 years, Congressional Budget Office Director Peter Orszag said
Hypertensive Label Changes Could Remedy Under-Treatment Problem -Cmte
More explicit dosing instructions in labeling might be the best way to urge physicians to more aggressively manage the under-treated hypertensive population, FDA's Cardio-Renal Advisory Committee said at an April 18 meeting to review a first-line claim for Bristol-Myers Squibb's Avalide